1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • May 2014
  • -
  • GlobalData
  • -
  • 59 pages

Summary

Table of Contents

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

ALKS-5461 is being developed by Alkermes as an adjunctive treatment for MDD in patients who have had an inadequate response to standard therapies. According to Alkermes, ALKS-5461 is expected to enter Phase III development during the first half of 2014. Following its very successful Phase II trial, the FDA granted Fast Track status for ALKS-5461 in order to facilitate its development and expedite its review by the regulatory authority (Alkermes, press release, October 10, 2013).

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on ALKS-5461 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for ALKS-5461 for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of ALKS-5461 performance
- Obtain sales forecast for ALKS-5461 from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Opportunity in Major Depressive Disorder Therapeutics in global market - 2017

Opportunity in Major Depressive Disorder Therapeutics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...

Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography (2017 - 2022)

Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The global antidepressants market is estimated to grow to approximately USD 13.4 billion by 2020, at a CAGR of 1.8%. Depression affects an estimated 121 million people worldwide and the antidepressant ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.